MEI Surpasses 5 Million in Usable Secondary Data from Electronic Medical Records
The Medical Engineering Institute (MEI) has recently achieved a significant milestone, surpassing 5 million records in their secondary data derived from electronic medical records (EMR). This achievement is a result of a strategic capital and business partnership established with KDDI Corporation in Tokyo, which commenced in 2023. MEI has been actively collaborating with over 60 healthcare institutions nationwide to build an advanced medical data platform, focusing on accumulating and analyzing EMR-derived data. Looking ahead, MEI aims to scale their usable EMR-derived data to approximately 10 million by the end of the fiscal year 2026.
MEI's approach includes leveraging its extensive partnerships within the medical community to collect comprehensive EMR-derived big data. With the combined expertise from MEI and KDDI in data analytics, they offer a range of services for data provision and analysis. The insights gained from this rich data resource have already been utilized in various pharmaceutical companies and governmental projects pertaining to medical data.
1. Outcome-Driven EMR Data:
MEI has gained support from over 60 medical institutions, particularly core hospitals, to gather real-world clinical data. This ensures that the collected data is comprehensive and actionable in real clinical settings. By utilizing their medical data warehouse system, CLISTA!, MEI effectively manages a wide range of data, encompassing EMR, administrative systems, and other clinical data sources.
Detailed information regarding tests, prescriptions, and procedures can be tracked over time, allowing for effective evaluation of drug efficacy and appropriate use assessments.
2. Current Medical Data from One Month Prior:
MEI maintains online connections with each collaborating medical institution, enabling them to provide data that is only about one month old. Timely access to current clinical data supports pharmaceutical companies and academic researchers in their endeavors to conduct up-to-date analyses.
3. High Analytical Power Through Integration of Medicine and Data Science:
MEI employs experienced physicians and data scientists, facilitating a multi-faceted approach to data analysis. This allows them to deeply engage with client challenges and provide tailored solutions. MEI supports clients in evidence generation from real-world data (RWD), protocol development, understanding patient journeys, and quickly adapting to market changes post-launch.
Clients interested in utilizing MEI RWD or who would like to view analysis case studies are encouraged to visit the following page for more details: MEI RWD Services.
As the realm of healthcare evolves, MEI’s commitment to maximizing the potential of electronic medical records stands to shape the future of medical analytics and research.
Overview of MEI RWD
MEI's approach includes leveraging its extensive partnerships within the medical community to collect comprehensive EMR-derived big data. With the combined expertise from MEI and KDDI in data analytics, they offer a range of services for data provision and analysis. The insights gained from this rich data resource have already been utilized in various pharmaceutical companies and governmental projects pertaining to medical data.
Key Features of MEI RWD:
1. Outcome-Driven EMR Data:
MEI has gained support from over 60 medical institutions, particularly core hospitals, to gather real-world clinical data. This ensures that the collected data is comprehensive and actionable in real clinical settings. By utilizing their medical data warehouse system, CLISTA!, MEI effectively manages a wide range of data, encompassing EMR, administrative systems, and other clinical data sources.
Detailed information regarding tests, prescriptions, and procedures can be tracked over time, allowing for effective evaluation of drug efficacy and appropriate use assessments.
2. Current Medical Data from One Month Prior:
MEI maintains online connections with each collaborating medical institution, enabling them to provide data that is only about one month old. Timely access to current clinical data supports pharmaceutical companies and academic researchers in their endeavors to conduct up-to-date analyses.
3. High Analytical Power Through Integration of Medicine and Data Science:
MEI employs experienced physicians and data scientists, facilitating a multi-faceted approach to data analysis. This allows them to deeply engage with client challenges and provide tailored solutions. MEI supports clients in evidence generation from real-world data (RWD), protocol development, understanding patient journeys, and quickly adapting to market changes post-launch.
Service Inquiries
Clients interested in utilizing MEI RWD or who would like to view analysis case studies are encouraged to visit the following page for more details: MEI RWD Services.
About Medical Engineering Institute
- - Company Name: Medical Engineering Institute Co., Ltd.
- - Business Scope: Development and provision of medical data platforms, analysis services using big data, hospital management analysis services, and related operations.
- - Established: December 2004
- - Headquarters: 3-141 Sakae-cho, Tsu City, Mie Prefecture, Japan
- - CEO: Kazuhiro Kasazaki, President
- - Capital: 100 million yen.
As the realm of healthcare evolves, MEI’s commitment to maximizing the potential of electronic medical records stands to shape the future of medical analytics and research.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.